Market Research Logo

Global Pediatric Epilepsy Therapeutics Market 2019-2023

Global Pediatric Epilepsy Therapeutics Market 2019-2023

About this market

The emergence of biomarkers to gain traction in the market. The world of epilepsy diagnostics is experiencing a trend of emerging biomarkers for epileptogenesis. Epilepsy is the disorder of repeated seizures; hence, these biomarkers for epileptogenesis are used to identify the spontaneity of the seizures. Technavio’s analysts have predicted that the pediatric epilepsy therapeutics market will register a CAGR of close to 6% by 2023.

Market Overview

Increasing demand for second and third-generation AEDs

The global pediatric epilepsy therapeutics market is witnessing a surge in the number of second-generation AEDs such as felbamate, lamotrigine, as they have low interaction and propensity for cognitive side-effects.

Adverse side effects and increasing social stigma

The global pediatric epilepsy therapeutics market has many approved drugs; however, they are associated with major side effects.

For the detailed list of factors that will drive and challenge the growth of the pediatric epilepsy therapeutics market during the 2019-2023, view our report.

Competitive Landscape

The market appears to be fragmented and with the presence of several companies including Eisai and GlaxoSmithKline the competitive environment is quite intense. Factors such as the emergence of biomarkers and the increasing demand for second and third-generation AEDs, will provide considerable growth opportunities to pediatric epilepsy therapeutics manufactures. Eisai, GlaxoSmithKline, Pfizer, UCB, and GW Pharmaceuticals are some of the major companies covered in this report.

‘With the presence of a considerable number of companies, this market appears to be fragmented. Some of the leading pediatric epilepsy therapeutic companies are forming alliances with organizations and vendors to develop therapeutics that a novel mechanism to make a smoother market entry.’


  • Executive summary
  • Scope of the report
  • Market landscape
    • Market ecosystem
      • Table Global epilepsy drugs market
      • Table Segments of global epilepsy drugs market
    • Market characteristics
      • Table Market characteristics
    • Market segmentation analysis
      • Table Market segments
  • Market sizing
    • Market definition
      • Table Various syndromes of pediatric epilepsy
      • Table Market definition - Inclusions and exclusions checklist
    • Market sizing 2018
      • Table Market size 2018
    • Market size and forecast 2018-2023
      • Table Global market: Size and forecast 2018-2023 ($ millions)
      • Table Global market: Year-over-year growth 2019-2023 (%)
  • Five forces analysis
    • Table Five forces analysis 2018
    • Table Five forces analysis 2023
    • Bargaining power of buyers
      • Table Bargaining power of buyers
    • Bargaining power of suppliers
      • Table Bargaining power of suppliers
    • Threat of new entrants
      • Table Threat of new entrants
    • Threat of substitutes
      • Table Threat of substitutes
    • Threat of rivalry
      • Table Threat of rivalry
    • Market condition
      • Table Market condition - Five forces 2018
  • Market segmentation by product
    • Table Product - Market share 2018-2023 (%)
    • Comparison by product
      • Table Comparison by product
    • Second-generation anti-epileptics - Market size and forecast 2018-2023
      • Table Second-generation anti-epileptics - Market size and forecast 2018-2023 ($ millions)
      • Table Second-generation anti-epileptics - Year-over-year growth 2019-2023 (%)
    • Third-generation anti-epileptics - Market size and forecast 2018-2023
      • Table Third-generation anti-epileptics - Market size and forecast 2018-2023 ($ millions)
      • Table Third-generation anti-epileptics - Year-over-year growth 2019-2023 (%)
    • First-generation anti-epileptics - Market size and forecast 2018-2023
      • Table First-generation anti-epileptics - Market size and forecast 2018-2023 ($ millions)
      • Table First-generation anti-epileptics approval timeline
      • Table First-generation anti-epileptics - Year-over-year growth 2019-2023 (%)
    • Market opportunity by product
      • Table Market opportunity by product
  • Customer landscape
    • Table Customer landscape
  • Geographic landscape
    • Geographic segmentation
      • Table Market share by geography 2018-2023 (%)
    • Geographic comparison
      • Table Geographic comparison
    • Americas - Market size and forecast 2018-2023
      • Table Americas - Market size and forecast 2018-2023 ($ millions)
      • Table Americas - Year-over-year growth 2019-2023 (%)
      • Table Top 3 countries in Americas
    • EMEA - Market size and forecast 2018-2023
      • Table EMEA - Market size and forecast 2018-2023 ($ millions)
      • Table EMEA - Year-over-year growth 2019-2023 (%)
      • Table Top 3 countries in EMEA
    • APAC - Market size and forecast 2018-2023
      • Table APAC - Market size and forecast 2018-2023 ($ millions)
      • Table APAC - Year-over-year growth 2019-2023 (%)
      • Table Top 3 countries in APAC
    • Key leading countries
      • Table Key leading countries
    • Market opportunity
      • Table Market opportunity
  • Decision framework
  • Drivers and challenges
    • Market drivers
      • Table Estimated number of prescriptions for BANZEL (February 1, 2015-May 31, 2017)
      • Table Overview of late-stage molecules in pipeline
    • Market challenges
      • Table Side effects of pediatric epilepsy therapeutics
      • Table Patent expiration for few noted AEDs
      • Table Impact of drivers and challenges
  • Market trends
  • Vendor landscape
    • Overview
      • Table Vendor landscape
    • Landscape disruption
      • Table Landscape disruption
    • Competitive scenario
  • Vendor analysis
    • Vendors covered
      • Table Vendors covered
    • Vendor classification
      • Table Vendor classification
    • Market positioning of vendors
      • Table Market positioning of vendors
    • Eisai
      • Table Eisai - Vendor overview
      • Table Eisai - Business segments
      • Table Eisai - Organizational developments
      • Table Eisai - Segment focus
      • Table Eisai - Geographic focus
      • Table Eisai - Key offerings
      • Table Eisai - Key customers
    • GlaxoSmithKline
      • Table GlaxoSmithKline - Vendor overview
      • Table GlaxoSmithKline - Business segments
      • Table GlaxoSmithKline - Organizational developments
      • Table GlaxoSmithKline - Segment focus
      • Table GlaxoSmithKline - Geographic focus
      • Table GlaxoSmithKline - Key offerings
      • Table GlaxoSmithKline - Key customers
    • GW Pharmaceuticals
      • Table GW Pharmaceuticals - Vendor overview
      • Table GW Pharmaceuticals - Business segments
      • Table GW Pharmaceuticals - Organizational developments
      • Table GW Pharmaceuticals - Segment focus
      • Table GW Pharmaceuticals - Geographic focus
      • Table GW Pharmaceuticals - Key offerings
      • Table GW Pharmaceuticals - Key customers
    • Pfizer
      • Table Pfizer - Vendor overview
      • Table Pfizer - Business segments
      • Table Pfizer - Organizational developments
      • Table Pfizer - Segment focus
      • Table Pfizer - Geographic focus
      • Table Pfizer - Key offerings
      • Table Pfizer - Key customers
    • UCB
      • Table UCB - Vendor overview
      • Table UCB - Business segments
      • Table UCB - Organizational developments
      • Table UCB – Geographic focus
      • Table UCB - Key offerings
      • Table UCB - Key customers
  • Appendix
    • Research methodology
    • List of abbreviations
  • Explore Technavio

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report